MedTrace Logo

Use of Wharton Jelly in Diabetic Nephropathy

NCT03288571 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-07-24

No results posted yet for this study

Summary

Wharton Jelly derived Mesenchymal stem cells will be injected in the renal parenchyma of patients with Diabetic Nephropathy

Conditions

  • Diabetic Nephropathies

Interventions

BIOLOGICAL

Wharton Jelly Mesenchymal stem cells

Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma

Sponsors & Collaborators

  • Jordan University of Science and Technology

    collaborator OTHER

  • An-Najah National University

    collaborator OTHER

  • Sophia Al-Adwan

    lead OTHER

Principal Investigators

  • Abdalla Awidi, MD · Cell Therapy Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2020-12-31
Completion
2021-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03288571 on ClinicalTrials.gov